Patents by Inventor Gerd Sutter

Gerd Sutter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200376051
    Abstract: The invention refers to new immuno-modulated replication-efficient Vaccinia virus strain (IOVA) and its derivatives for the use in medicine.
    Type: Application
    Filed: December 3, 2018
    Publication date: December 3, 2020
    Inventors: Gerd SUTTER, Juan José ROJAS EXPOSITO
  • Patent number: 8197825
    Abstract: The present invention relates to recombinant vaccinia viruses derived from the modified vaccinia virus Ankara (MVA) and containing and capable of expressing foreign genes which are inserted at the site of a naturally occurring deletion in the MVA genome, and the use of such recombinant MVA viruses for the production of polypeptides, e.g. antigens or therapeutic agents, or viral vectors for gene therapy, and the use of such recombinant MVA viruses encoding antigens as vaccines.
    Type: Grant
    Filed: June 14, 2010
    Date of Patent: June 12, 2012
    Assignee: GSF-Forschungszentrum fur Umwelt und Gesundheit GmbH
    Inventors: Gerd Sutter, Marion Ohlmann, Volker Erfle
  • Patent number: 8153138
    Abstract: The present invention relates to recombinant vaccinia viruses derived from the modified vaccinia virus Ankara (MVA) and containing and capable of expressing foreign genes which are inserted at the site of a naturally occurring deletion in the MVA genome, and the use of such recombinant MVA viruses for the production of polypeptides, e.g. antigens or therapeutic agents, or viral vectors for gene therapy, and the use of such recombinant MVA viruses encoding antigens as vaccines.
    Type: Grant
    Filed: September 19, 2006
    Date of Patent: April 10, 2012
    Assignee: GSF-Forschungszentrum fur Umwelt und Gesundheit GmbH
    Inventors: Gerd Sutter, Marion Ohlmann, Volker Erfle
  • Publication number: 20110293656
    Abstract: The invention relates to recombinant MVA which is capable of expressing structural HCV antigens, functional parts of said structural antigens or epitopes of said structural antigens. The invention further relates to a pharmaceutical composition, especially in the form of a vaccine and containing the recombinant MVA according to the invention, to eukaryotic cells that contain the inventive recombinant MVA and to various uses of the recombinant MVA, for example for producing recombinant structural proteins, for producing a pharmaceutical preparation that is suitable for the therapy and prophylaxis of HCV infections and diseases thereby caused. The invention further relates to methods for producing recombinant MVA and recombinant structural HCV polypeptides encoded by said recombinant MVA, and to DNA or RNA of said recombinant MVA.
    Type: Application
    Filed: May 18, 2011
    Publication date: December 1, 2011
    Inventors: Gerd Sutter, Volker Erfle, Caroline Staib, Yuan Wang, Guangdi Li, Li-Xin Zhu
  • Publication number: 20110020391
    Abstract: The present invention relates to the use of a recombinant modified vaccinia virus Ankara (MVA) comprising a heterologous nucleic acid for the production of a medicament in particular a vaccine, wherein the sequence of heterologous nucleic acid is from influenza A virus class H5 antigen. In a further aspect of the invention the invention relates to a recombinant modified vaccinia virus Ankara (MVA) comprising a heterologous nucleic acid, wherein (a) the heterologous nucleic acid is incorporated into a non-essential site within the genome of MVA, (b) the heterologous nucleic acid is under the control of a vaccinia virus promoter, or orthopoxvirus promoter, or poxvirus-specific promoter and, (c) the heterologous nucleic acid is selected from the group of nucleic acids encoding a gene or a part of a gene from an influenza A virus class H5.
    Type: Application
    Filed: November 16, 2007
    Publication date: January 27, 2011
    Applicant: PAUL-EHRLICH-INSTITUT BUNDESAMT FUR SERA UND IMPFSTOFFE
    Inventors: Yasemin Süzer, Johannes Löwer, Gerd Sutter, A.D.M.E. Osterhaus, G.F Rimmelzwaan, Joost Kreijtz
  • Publication number: 20100291139
    Abstract: The present invention relates to recombinant vaccinia viruses derived from the modified vaccinia virus Ankara (MVA) and containing and capable of expressing foreign genes which are inserted at the site of a naturally occurring deletion in the MVA genome, and the use of such recombinant MVA viruses for the production of polypeptides, e.g. antigens or therapeutic agents, or viral vectors for gene therapy, and the use of such recombinant MVA viruses encoding antigens as vaccines.
    Type: Application
    Filed: June 14, 2010
    Publication date: November 18, 2010
    Inventors: GERD SUTTER, Marion Ohlmann, Volker Erfle
  • Publication number: 20100266630
    Abstract: The present invention relates to recombinant vaccinia viruses derived from the modified vaccinia virus Ankara (MVA) and containing and capable of expressing foreign genes which are inserted at the site of a naturally occurring deletion in the MVA genome, and the use of such recombinant MVA viruses for the production of polypeptides, e.g. antigens or therapeutic agents, or viral vectors for gene therapy, and the use of such recombinant MVA viruses encoding antigens as vaccines.
    Type: Application
    Filed: September 19, 2006
    Publication date: October 21, 2010
    Applicant: GSF-Forschungszentrum Fur Umwelt und Gesundheit GmbH
    Inventors: Gerd Sutter, Marion Ohlmann, Volker Erfle
  • Patent number: 7767209
    Abstract: The present invention is directed to a MVA mutant and its use in the immunotherapy and vaccination against numerous diseases, in particular in the prevention and therapy of cancer and infectious diseases.
    Type: Grant
    Filed: March 14, 2006
    Date of Patent: August 3, 2010
    Assignee: GSF-Forschungszentrum fuer Umwelt und Gesundheit GmbH
    Inventors: Caroline Staib, Gerd Sutter, Sigried Kiesling, Volker Erfle
  • Publication number: 20090238843
    Abstract: The invention relates to recombinant MVA which is capable of expressing structural HCV antigens, functional parts of said structural antigens or epitopes of said structural antigens. The invention further relates to a pharmaceutical composition, especially in the form of a vaccine and containing the recombinant MVA according to the invention, to eukaryotic cells that contain the inventive recombinant MVA and to various uses of the recombinant MVA, for example for producing recombinant structural proteins, for producing a pharmaceutical preparation that is suitable for the therapy and prophylaxis of HCV infections and diseases thereby caused. The invention further relates to methods for producing recombinant MVA and recombinant structural HCV polypeptides encoded by said recombinant MVA, and to DNA or RNA of said recombinant MVA.
    Type: Application
    Filed: June 2, 2009
    Publication date: September 24, 2009
    Inventors: Gerd Sutter, Volker Erfle, Caroline Staib, Yuan Wang, Guangdi Li, Li-Xin Zhu
  • Publication number: 20090191157
    Abstract: The present invention relates to the use of a recombinant modified vaccinia virus Ankara (MVA) comprising a heterologous nucleic acid for the production of a medicament for the prevention and/or treatment of type I hypersensitivity in a living animal including humans. The invention further relates to a recombinant modified vaccinia virus Ankara (MVA) comprising a heterologous nucleic acid, wherein the heterologous nucleic acid is incorporated into a non-essential region of the genome of the MVA, the heterologous nucleic acid is under the control of, e.g. a vaccinia virus-specific promoter and, the heterologous nucleic acid is selected from the group of nucleic acids encoding an allergen selected from the group of weed pollens, grass pollens, tree pollens, mites, animals, fungi, insects, rubber, worms, human autoallergens, and foods.
    Type: Application
    Filed: March 14, 2007
    Publication date: July 30, 2009
    Applicant: PAUL-ENRLICH-INSTITUT BUNDESAMT FUER SERA UND IMPFSTOFFE
    Inventors: Melanie Albrecht, Gerd Sutter, Yasemin Suezer, Gerald Reese, Stefan Vieths, Caroline Staib
  • Publication number: 20080075694
    Abstract: The present invention is directed to a recombinant MVA, which carries a nucleic acid sequence coding for a fusion protein. The present invention is further directed to a kit of parts containing said recombinant MVA as well as to a method for enhancing T cell responses in a mammal.
    Type: Application
    Filed: July 19, 2007
    Publication date: March 27, 2008
    Inventors: Ingo Drexler, Gerd Sutter, Georg Gasteiger, Volker Erfle
  • Publication number: 20070160627
    Abstract: The present invention is directed to a MVA mutant and its use in the immunotherapy and vaccination against numerous diseases, in particular in the prevention and therapy of cancer and infectious diseases.
    Type: Application
    Filed: March 14, 2006
    Publication date: July 12, 2007
    Inventors: Caroline Staib, Gerd Sutter, Sigried Kiesling, Volker Erfle
  • Patent number: 7198934
    Abstract: The present invention relates to recombinant vaccinia viruses derived from the modified vaccinia virus Ankara (MVA) and containing and capable of expressing foreign genes which are inserted at the site of a naturally occurring deletion in the MVA genome, and the use of such recombinant MVA viruses for the production of polypeptides, e.g. antigens or therapeutic agents, or viral vectors for gene therapy, and the use of such recombinant MVA viruses encoding antigens as vaccines.
    Type: Grant
    Filed: May 15, 2002
    Date of Patent: April 3, 2007
    Assignee: GSF-Forschungszentrum fur Umwelt und Gesundheit GmbH
    Inventors: Gerd Sutter, Marion Ohlmann, Volker Erfle
  • Publication number: 20070071769
    Abstract: The present invention relates to recombinant vaccinia viruses derived from the modified vaccinia virus Ankara (MVA) and containing and capable of expressing foreign genes which are inserted at the site of a naturally occurring deletion in the MVA genome, and the use of such recombinant MVA viruses for the production of polypeptides, e.g. antigens or therapeutic agents, or viral vectors for gene therapy, and the use of such recombinant MVA viruses encoding antigens as vaccines.
    Type: Application
    Filed: September 19, 2006
    Publication date: March 29, 2007
    Applicant: GSF-Forschungszentrum Fur Umwelt und Gesundheit GmbH
    Inventors: Gerd Sutter, Marion Ohlmann, Volker Erfle
  • Publication number: 20070071770
    Abstract: The present invention relates to recombinant vaccinia viruses derived from the modified vaccinia virus Ankara (MVA) and containing and capable of expressing foreign genes which are inserted at the site of a naturally occurring deletion in the MVA genome, and the use of such recombinant MVA viruses for the production of polypeptides, e.g. antigens or therapeutic agents, or viral vectors for gene therapy, and the use of such recombinant MVA viruses encoding antigens as vaccines.
    Type: Application
    Filed: September 19, 2006
    Publication date: March 29, 2007
    Applicant: GSF-Forschungszentrum Fur Umwelt und Gesundheit GmbH
    Inventors: Gerd Sutter, Marion Ohlmann, Volker Erfle
  • Patent number: 7150874
    Abstract: A new DNA vector is disclosed comprising a nucleic acid sequence useful for inserting heterologous sequences into the genome of poxviruses by homologous recombination. Also disclosed are recombinant poxviruses carrying heterologous coding sequences transferred by the DNA vector.
    Type: Grant
    Filed: September 23, 2003
    Date of Patent: December 19, 2006
    Assignee: GFS Forschungszentrum fur Umwelt und Gesundheit GmbH
    Inventors: Stefan Wintersperger, Robert Baier, Gerd Sutter, Marion Ohlmann, Volker Erfle
  • Publication number: 20060127413
    Abstract: This invention relates to recombinant viruses based on MVA, which comprise at least one nucleic acid coding for a Plasmodium falciparum MSP-1 protein, a fragment or mutein of it. Furthermore, methods for the production of the recombinant viruses, virus-containing vaccines and the use of the recombinant viruses for the prophylaxis and/or therapy of malaria are provided.
    Type: Application
    Filed: September 26, 2003
    Publication date: June 15, 2006
    Inventors: Gerd Sutter, Hermann Bujard, Nicole Westerfeld, Miao Jun
  • Patent number: 7049145
    Abstract: The present invention relates to mutant MVA vaccinia viruses, which are used for the generation of recombinant MVA viruses, as well as host cells, which have been infected with these mutant MVA viruses. The present invention further relates to DNA-vector constructs, and a method for the generation of recombinant MVA by using the mutant MVA viruses and the DNA-vector constructs. The mutant MVA vaccinia viruses of the present invention are characterized in that the MVA ORF 050L gene or a functional part thereof has been inactivated in the viral genome.
    Type: Grant
    Filed: September 11, 2002
    Date of Patent: May 23, 2006
    Assignee: GSF-Forschungszentrum fur Umwelt und Gesundheit, GmbH
    Inventors: Volker Erfle, Simone Hornemann, Gerd Sutter
  • Publication number: 20060002896
    Abstract: The present invention relates to MVA mutants, which can be used for the generation of recombinant MVA viruses, as well as host cells, which have been infected with these mutant MVA viruses. The present invention further relates to DNA-vector constructs, and a method for the generation of recombinant MVA by using the mutant MVA viruses and the DNA-vector constructs.
    Type: Application
    Filed: June 10, 2005
    Publication date: January 5, 2006
    Inventors: Caroline Staib, Marianne Loewel, Volker Erfle, Gerd Sutter
  • Publication number: 20050287162
    Abstract: The invention relates to a recombinant fowlpox virus (FWPV) and a DNA vector containing gene sequences for one such recombinant fowlpox virus. The invention also relates to a pharmaceutical composition containing said recombinant fowlpox virus or a DNA vector, to the use of said recombinant fowlpox virus for treating infectious diseases or tumour diseases, and to a method for producing said recombinant fowlpox virus or DNA vector. The invention further relates to eukaryote cells or prokaryote cells containing the recombinant DNA vector or the recombinant fowlpox virus. The invention is based on the identification of the FWPV-F11L gene as a novel insertion site for foreign DNA.
    Type: Application
    Filed: May 13, 2003
    Publication date: December 29, 2005
    Inventors: Robert Baier, Denise Boulanger, Volker Erfle, Gerd Sutter